Halozyme Therapeutics Exceeds Q4 Expectations with Solid Earnings and Revenue
Halozyme Therapeutics Inc. (HALO) reported robust financial results for the fourth quarter of 2023, surpassing market estimates.
Key Financial Highlights:
* Net income: $137 million, or $1.06 per share
* Adjusted earnings: $1.26 per share
* Revenue: $298 million
These results beat analysts' projections of $1.16 EPS and revenue of $284 million.
Annual Performance:
In 2023, Halozyme achieved the following:
* Net income: $444.1 million, or $3.43 per share
* Revenue: $1.02 billion
Outlook:
The company anticipates full-year earnings per share in the range of $4.95 to $5.35 and revenue between $1.15 billion and $1.23 billion for 2024.
This financial performance demonstrates Halozyme's continued growth and its commitment to delivering innovative biopharmaceutical solutions.